Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study.
clinical trial phase II
hepatocellular carcinoma
multicenter study
stereotactic body radiotherapy
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
revised:
20
10
2020
received:
14
08
2020
accepted:
05
11
2020
pubmed:
21
11
2020
medline:
21
11
2020
entrez:
20
11
2020
Statut:
ppublish
Résumé
To prospectively evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) for patients with previously untreated solitary primary hepatocellular carcinoma (HCC). The main eligibility criteria included the following: (1) primary solitary HCC; (2) no prior treatment for HCC; (3) Child-Turcotte-Pugh score of seven or less; and (4) unsuitability for or refusal of surgery and radiofrequency ablation (RFA). The prescribed dose of SBRT was 40 Gy in five fractions. The primary endpoint was 3-year overall survival (OS); the secondary endpoints included local progression-free survival (LPFS), local control (LC), and adverse events. The accrual target was 60 patients, expecting a 3-year OS of 70% with a 50% threshold. Between 2014 and 2018, 36 patients were enrolled; enrollment was closed early because of slow accrual. The median tumor size was 2.3 cm. The median follow-up at the time of evaluation was 20.8 months. The 3-year OS was 78% (95% confidence interval [CI]: 53%-90%). The 3-year LPFS and LC proportion were 73% (95% CI: 48%-87%) and 90% (95% CI: 65%-97%), respectively. Grade 3 or higher SBRT-related toxicities were observed in four patients (11%), and grade five toxicities were not observed. This study showed acceptably low incidence of SBRT-related toxicities. LC and OS after SBRT were comparable for previously untreated solitary HCC for patients unfit for resection and RFA. Although a definitive conclusion cannot be drawn by this study, the promising results indicate that SBRT may be an alternative option in the management of early HCC.
Types de publication
Journal Article
Langues
eng
Pagination
461-471Subventions
Organisme : Japan Society for the Promotion of Science (JSPS) KAKENHI
ID : JP16K10401
Informations de copyright
© 2020 The Japan Society of Hepatology.
Références
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.
Kudo M , Izumi N , Kubo S , Kokudo N , Sakamoto M , Shiina S , et al. Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2020;50:15-46.
Izumi N , Hasegawa K , Nishioka Y , Takayama T , Yamanaka N , Kudo M , et al. A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial). ASCO 2019 annual meeting abstract #4022.
Wahl DR , Stenmark MH , Tao Y , Pollom EL , Caoili EM , Lawrence TS , et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34:452-9.
NCCN clinical practice guidelines in Oncology (NCCN Guidelines®) hepatobiliary cancers ver. 3. 2019 [homepage on the internet]. Fort Washington: National Comprehensive Cancer Network® ; [updated 2019 Aug 1; cited 2019 Oct 28]. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf
Andolino DL , Johnson CS , Maluccio M , Kwo P , Tecto AJ , Zook J , et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;81:e447-53.
Kang JK , Kim MS , Cho CK , Yang AM , Yoo HJ , Kim JH , et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete trans arterial chemoembolization. Cancer. 2012;118:5424-31.
Takeda A , Sanuki N , Tsurugai Y , Iwabuchi S , Matsunaga K , Ebinuma H , et al. Phase 2 study of stereotactic body radiotherapy and optional trans arterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer. 2016;122:2041-9.
Sanuki N , Takeda A , Oku Y , Mizuno T , Aoki Y , Eriguchi T , et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol. 2014;53:399-404.
Kubo K , Kimura T , Aikata H , Takahashi S , Takeuchi Y , Takahashi I , et al. Long-term outcome of stereotactic body radiotherapy for patients with small hepatocellular carcinoma. Hepatol Res. 2018;48:701-7.
Marrero JA , Kulik LM , Sirlin C , Zhu AX , Finn RS , Abecassis MM , et al. Diagnosis, staging and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68:723-50.
Lasley FD , Mannina EM , Johnson CS , Perkins SM , Althouse S , Maluccio M , et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol. 2015;5:e443-e449.
Kim JW , Kim DY , Han KH , Seong J . Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma. Dig Liver Dis. 2019;51:445-51.
Bujold A , Massey CA , Kim JJ , Brierley J , Cho C , Wong RKS , et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631-9.
Jang W , Bae SH , Kim MS , Han CJ , Park SC , Kim SB , et al. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: safety and efficacy. Cancer. 2020;126:363-72.
van't Riet A , Mak AC , Moerland MA , Elders LH , van der Zee WA . Conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate. Int J Radiat Oncol Biol Phys. 1997;37:731-6.
Lencioni R , Llovet JM . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
Brookmeyer R , Crowley, JJ . A confidence interval for the median survival time. Biometrics. 1982;38:29-41.
Eriguchi T , Takeda A , Oku Y , Ishikura S , Kimura T , Ozawa S , et al. Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma - benchmark for a prospective multi-institutional study. Radiat Oncol. 2013;8:113.
Kokudo N , Takemura N , Hasegawa K , Takayama T , Kubo S , Shimada M , et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49:1109-13.
Omata M , Cheng AL , Kokudo N , Kudo M , Lee JM , Jia J , et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;31:317-70.
Takeda A , Sanuki N , Eriguchi T , Kobayashi T , Iwabutchi S , Matsunaga K , et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:372-9.
Huang J , Lvnan Y , Cheng Z , Wu H , Du L , Wang J , et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252:903-12.
Feng K , Yan J , Li X , Xia F , Ma K , Wang S , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57:794-802.
Kim YS , Lim HK , Rhim H , Lee MW , Choi D , Lee WJ , et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58:89-97.
European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-43.
Durand-Labrunie J , Baumann AS , Ayav A , Laurent V , Boleslawski E , Cattan S , et al. Curative irradiation treatment of hepatocellular carcinoma: a multicenter Phase 2 trial. Int J Radiat Oncol Biol Phys. 2020;107:116-25.
Miyayama S , Matsui O , Yamashiro M , Ryu Y , Kaito K , Ozaki K , et al. Ultraselective transcatheter arterial chemoembolization with a 2-F tip microcatheter for small hepatocellular caicinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol. 2007;18:365-76.
Takayasu K , Arii S , Kudo M , Ichida T , Matsui O , Izumi N , et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012;56:886-92.
Su TS , Liang P , Liang J , Lu HZ , Jiang HY , Cheng T , et al. Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2017;98:639-46.
Spair E , Tao Y , Schipper MJ , Bazzi L , Novelli PM , Devlin P , et al. Stereotactic body radiation therapy as an alternative to trans arterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:122-30.
Huo RY , Eslick GD . Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma. A systematic review and meta-analysis. JAMA Oncol. 2015;6:756-65.
Hara K , Takeda A , Tsurugai Y , Saigusa Y , Sanuki N , Eriguchi T , et al. Radiotherapy for Hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis. Hepatology. 2019:0:1-13.
Rajyaguru DJ , Borgert AJ , Smith AL , Thomes RM , Conway PD , Halfdanarson TR , et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in non-surgically managed patients: analysis of the National Cancer Database. J Clin Oncol. 2018;36:600-8.
Kim N , Cheng J , Jung I , Liang JD , Shih YL , Huang WY , et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol. 2020;73:121-129.
Brunelli A . It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible. J Thorac Cardiovasc Surg. 2018;156:1247-8.
Bertolaccini L , Spaggiari L . Should we use the Olympic spirit in the controversy between surgery and stereotactic ablative radiotherapy in operable early stage not small cell lung cancer? Ann Thorac Surg. 2020;110:235.